United Kingdom Nephrology and Urology Devices Market Outlook to 2025 - Renal Dialysis Equipment

Table of Contents

• 1.1 List of Tables 4
• 1.2 List of Figures 4

2 Introduction 6

• 2.1 What Is This Report About? 6
• 2.2 Nephrology and Urology Devices Market Segmentation 6
• 2.3 Definitions of Markets Covered in the Report 7

3 Nephrology and Urology Devices Market, United Kingdom 9

• 3.1 Nephrology and Urology Devices Market, United Kingdom, Revenue ($m), 2015-2025 9
• 3.2 Nephrology and Urology Devices Market, United Kingdom, Revenue ($m), 2015-2025 11
• 3.3 Nephrology and Urology Devices Market, United Kingdom, Volume (Units), 2015-2025 13
• 3.4 Nephrology and Urology Devices Market, United Kingdom, Volume (Units), 2015-2025 15
• 3.5 Nephrology and Urology Devices Market, United Kingdom, Company Share by Revenue ($m), 2019 17

4 Renal Dialysis Equipment Market, United Kingdom 19

• 4.1 Renal Dialysis Equipment Market, United Kingdom, Revenue Mix ($m), 2019 19
• 4.2 Renal Dialysis Equipment Market, United Kingdom, Segment Contribution (%), 2019 20
• 4.3 Renal Dialysis Equipment Market, United Kingdom, Revenue ($m), 2015-2025 21
  • 4.3.1 Dialysis Accessories Market, United Kingdom, Revenue ($m), by Segment, 2015-2025 23
  • 4.3.2 Dialysis Machines Market, United Kingdom, Revenue ($m), by Segment, 2015-2025 26
  • 4.3.3 Vascular Access Devices for Hemodialysis Market, United Kingdom, Revenue ($m), by Segment, 2015-2025 28
• 4.4 Renal Dialysis Equipment Market, United Kingdom, Volume (Units), 2015-2025 31
  • 4.4.1 Dialysis Accessories Market, United Kingdom, Volume (Units) by Segment, 2015-2025 33
  • 4.4.2 Dialysis Machines Market, United Kingdom, Volume (Units) by Segment, 2015-2025 36
  • 4.4.3 Vascular Access Devices for Hemodialysis Market, United Kingdom, Volume (Units) by Segment, 2015-2025 38
• 4.5 Renal Dialysis Equipment Market, United Kingdom, Average Price ($), 2015-2025 41
• 4.6 Renal Dialysis Equipment Market, United Kingdom, Distribution Share by Revenue ($m), 2019 43
• 4.7 Renal Dialysis Equipment Market, United Kingdom, Company Share by Revenue ($m), 2019 44

5 Overview of Key Companies in United Kingdom, Nephrology and Urology Devices Market 46

• 5.1 Fresenius Medical Care AG & Co KGaA 46
  • 5.1.1 Company Overview 46
• 5.2 Nipro Corp 46
  • 5.2.1 Company Overview 46
• 5.3 Baxter International Inc 46
  • 5.3.1 Company Overview 46
• 5.4 Asahi Kasei Corp 47
  • 5.4.1 Company Overview 47
• 5.5 B. Braun Melsungen AG 47
  • 5.5.1 Company Overview 47
• 5.6 Toray Medical Co Ltd 47
  • 5.6.1 Company Overview 47
• 5.7 CR Bard Inc 48
  • 5.7.1 Company Overview 48

6 Nephrology and Urology Devices Market Pipeline Products 49

7 Financial Deals Landscape 51

• 7.1 Equity Offerings 51
  • 7.1.1 Renalytix AI to Raise USD14.98 Million in Private Placement of Shares 51
• 7.2 Partnerships 52
  • 7.2.1 Osprey Medical to Enter into Distribution Agreement with GE Healthcare 52
• 7.3 Venture Financing 53
  • 7.3.1 Invizius Raises Funds through Equity Financing 53
  • 7.3.2 Invizius Raises USD3.4 Million in Venture Financing 55
  • 7.3.3 Quanta Dialysis Technologies Raises USD47 Million in Series C Financing 56

8 Recent Developments 58

• 8.1 Corporate Communications 58
  • 8.1.1 Mar 02, 2020: Stryker announces new Investor Relations leader 58
  • 8.1.2 Feb 27, 2020: ConvaTec Group: Non-executive director appointment 58
  • 8.1.3 Feb 04, 2020: Solvay Ventures invests in Invizius 59
  • 8.1.4 Oct 14, 2019: Renalytix AI: Board appointment 59
  • 8.1.5 Sep 30, 2019: Johnson & Johnson appoints Carlton Lawson to area Managing Director, Consumer, Northern Europe 60
  • 8.1.6 Sep 30, 2019: Renalytix AI: Update on non-executive director appointment 60
  • 8.1.7 Aug 19, 2019: John McAdam appointed Chairman of ConvaTec 61
  • 8.1.8 Jul 29, 2019: RenalytixAI appoints Thomas McLain as President and Chief Commercial Officer 61
  • 8.1.9 Jul 24, 2019: Former Medtronic Executive Sean Ginney named VP of Sales at Current Health 62
  • 8.1.10 Jun 25, 2019: ConvaTec Group: Board Change 63
• 8.2 Financial Announcements 63
  • 8.2.1 Feb 28, 2020: ConvaTec Group: Audited annual results for the twelve months ended 31 December 2019 63
  • 8.2.2 Jan 29, 2020: Concepta - Trading Update 64
  • 8.2.3 Sep 17, 2019: Novita signs key UK partner supply agreement 66
  • 8.2.4 Sep 03, 2019: Renalytix AI: Preliminary results 68
  • 8.2.5 Aug 29, 2019: CooperCompanies announces third quarter 2019 results 69
  • 8.2.6 Aug 01, 2019: ConvaTec Group first half results 2019 70
  • 8.2.7 Jul 24, 2019: Boston Scientific announces results for second quarter 2019 77
• 8.3 Government and Public Interest 78
  • 8.3.1 Jul 12, 2019: Renalytix AI: US executive order on advancing american kidney health 78
• 8.4 Legal And Regulatory 79
  • 8.4.1 Sep 30, 2019: Mallinckrodt finalizes settlement to resolve "Track 1" opioid cases with the Ohio Counties of Cuyahoga and Summit 79
• 8.5 Other Significant Developments 80
  • 8.5.1 Mar 05, 2020: ADDvise signs a new agreement with Laborie with a total order value of at least MSEK 50 80
  • 8.5.2 Oct 09, 2019: £2.75 million spinout deal offers dialysis hope 80
  • 8.5.3 Aug 01, 2019: Kane Biotech announces new funding granted from CanExport Program 81
  • 8.5.4 Jul 08, 2019: Terumo invests 26 Million Euro in new production lines for its Belgian Facility 81
  • 8.5.5 Jun 27, 2019: Genmab announces U.S. FDA approval of DARZALEX (daratumumab) in combination with Lenalidomide and Dexamethasone in frontline multiple myeloma 82
  • 8.5.6 Apr 09, 2019: Fist Assist Devices announces approval of FACT by University of Chicago Medical Center 84
• 8.6 Strategy And Business Planning 84
  • 8.6.1 Jan 08, 2020: Renalytix AI: New commercial testing facility opens in Utah 84
  • 8.6.2 Dec 04, 2019: Lumeon and Medtronic partner to deliver new models of care in Europe 86

9 Appendix 87

• 9.1 Research Methodology 88
  • 9.1.1 Coverage 88
  • 9.1.2 Secondary Research 88
  • 9.1.3 Primary Research 89
  • 9.1.4 Market Modeling and Forecasting 89
  • 9.1.5 Company Share Analysis 91
  • 9.1.6 Distribution Share Analysis 91
  • 9.1.7 Benchmarking 92
• 9.2 GlobalData Consulting 92
• 9.3 Contact Us 93